HMGB1: Endogenous Danger Signaling-Reference-Cited by-同舟云学术

HMGB1: Endogenous Danger Signaling

Published:2008-04-11 Issue:7-8 Volume:14 Page:476-484
ISSN:1076-1551
Container-title:Molecular Medicine
language:en
Short-container-title:Mol Med

Author:

Klune John R.,Dhupar Rajeev,Cardinal Jon,Billiar Timothy R.,Tsung Allan

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.2119/2008-00034.Klune.pdf

Reference126 articles.

1. Medawar P. (1964) Immunological Tolerance. In: Nobel Lectures, Physiology or Medicine 1942–1962. Elsevier Publishing Company, Amsterdam, The Netherlands.

2. Medawar PB, Woodruff MF. (1958) The induction of tolerance by skin homografts on newborn rats. Immunology. 1:27–35.

3. Matzinger P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991–1045.

4. Matzinger P. (2002) The danger model: a renewed sense of self. Science. 296:301–305.

5. Medzhitov R, Janeway CA Jr. (2002) Decoding the patterns of self and nonself by the innate immune system. Science. 296:298–300.

Cited by 665 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between high-mobility group box-l and cognitive impairments induced by myocardial ischemia-reperfusion in elderly rats;Experimental Gerontology;2024-10

2. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone;Biomedicine & Pharmacotherapy;2024-07

3. An Investigation of the Inflammatory Landscape in the Brain and Bone Marrow of the APP/PS1 Mouse;Journal of Alzheimer's Disease Reports;2024-06-21

4. Testosterone Exacerbates the Formation of Liver Cancer Induced by Environmental N-Nitrosamines Exposure: Potential Mechanisms and Implications for Human Health;OncoTargets and Therapy;2024-05

5. High mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma;International Immunopharmacology;2024-05